Evogene Quarterly Update  Validation Results & Updates  August 2016 

 Safe Harbor Statement  *  This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.  The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.  

 Introducing Evogene  *  Located HQ - Rehovot, IsraelR&D site - St. Louis, USA~200 employees, 80% R&DListed - TASE (2007); NYSE (2013)Innovative discovery technology - broadly applicable proprietary platform, combining cutting-edge computational capabilities with interdisciplinary biological expertise Two R&D hubs for improving crop productivity Crop enhancement - yield, drought tolerance and fertilizer use efficiencyCrop protection - insect resistance, disease and weedsCollaborations with world-leading agriculture companies - Bayer, BASF, DuPont, Monsanto, SyngentaTargeting 3 major markets Seed traits - ~$37B1Ag-Chemicals - ~$55B2Ag-Biologicals - ~$4B3  1 Source: Phillips McDougall , 20162 Source: Phillips McDougall, 20153 Source: Research & Markets, 2016   Crop Enhancement   Seed Traits  Ag-Chemicals  Ag-Biologicals  Crop Protection  

 *  Improved seed traits 

 *  WW Seed Market, $B  *  *  *  *  40.6  Growing market*        Yield  $1.5B  $1.2B  Drought tolerance  $0.65B  $0.45B  Insect resistance  $3.2B  $0.5B  Disease resistance  $1B  $1B  Herbicide tolerance  $3.5B  $1.5B  Corn  Soy  Trait potential – per crop**  *  Conventional seeds  Biotechnology seeds  Biotechnology seedprice to farmers  Conventional seed  Seed traits   * Source: Phillips McDougall   ** Source: Internal analysis  Improved seed traitsMarket overview & potential  Examples – trait values   37.2  2015  2014  2013  2012  2011  2010 

 *  Subset of genes improved predicted trait attributes for yield - Further testing undertaken for these genes as well as additional previously discovered genes  Plant genes demonstrated potential to achieve yield enhancement in corn and soybean  Improved seed traitsYield & abiotic stress tolerance - recent results & updates 

 *  Microbial genes demonstrated activity against target insects  Examples for positive microbial genes – demonstrated positive results in insect feeding assay   Improved seed traitsInsect Control – recent results & updates 

 *  Example for active gene – activity in soybean model system  Plant genes reducing nematode infection by up to 70%  Plant genes conferring resistance to disease in Banana   Example for active gene – activity in Banana against Black Sigatoka disease  Eight events were evaluated, statistically significantMagnitude of results repeated in two generation  *BSI -    100 X (youngest leaf spotted -1 ) Number of standing leaves  EVO18010048 results in two tests  Improved seed traitsNematode & disease resistance - recent results & updates  First genes in stable soybean transformation – planned to enter validation in 2017  Undergoing larger scale field trial in Central America 

 *  Improved seed traitsPromoters– recent results & updates  Promoters* with initial validation for specific expression patterns  Examples for successful promoter predictions – initial positive results in model plant validation   *Segments of DNA that determine expression patterns for genes. Such promoters when used with appropriate genes are an essential component of improving seed trait efficacy.  

 *  Innovative Ag-Chemicals 

 *  Huge market - ~$55B* in 2014  Need for herbicide innovation  ($14.85B)  ($14.3B)  ($1.65B)  Herbicides  Insecticides  Fungicides  Others  * Source: Phillips McDougall , 2014  Herbicides - combat invasive weeds  Rising weed resistance for existing herbicides   Growing need for innovation   Increasing regulation pressure  Herbicide TargetA macro-molecule within the weed essential for weed life  Herbicide CompoundChemical inhibiting Herbicide target leading to weed death  inhibition  Annual damage estimatedat up to $100B  Innovative Ag-ChemicalsMarket overview & potential  ($24.2B)  Need for Herbicide Compounds inhibiting new Mode of Action – inhibiting new Herbicide Targets 

 *  Example for Herbicide Target - induced inhibition of targets leads to plant death  Herbicide Targets validated in plant system  Compounds displaying herbicide activity against weeds   Example for Compound - displaying herbicidal activity In greenhouse  Target inhibition - dying plant  Normal target activity - healthy plant   EVOHRB106  EVO AG1345*  No treatment (negativecontrol)  Commercial herbicide (positivecontrol)  *Prior to optimization  Panel of weeds – 15 days post application  Innovative Ag-ChemicalsHerbicides – recent results & updates 

 *  Novel Ag-Biologicals 

 *  Major ag companies taking significant steps to enter this market  Harnessing the power of Microbiome  acquired  joint venture  acquired  acquired  acquired  Data based on Research and Markets, 2016  Growing market*  E  Novel Ag-BiologicalsMarket overview & potential  *  Human microbiome understanding leveraged into plant  Enabled by availability of new and affordable genomic data  16s-rRNA sequencing  Metagenomics  Next generation sequencing 

 *  Microbials impacting model & target crops  Example for microbial ‘hit’- positive results in greenhouse screens  Model plant - Brachypodium yield assay:Improved vegetative & yield responses & earlier heading  Target crop - Corn vegetative assay* : Improved vegetative responses   No treatment  No treatment  EVM00100869  Over 18% grain yield improvement  % Improvementcompared to control  58  54  50  46  EVM00100869  * Testing conducted during early growth stage – between germination & flowering  Novel Ag-BiologicalsBiostimulants – recent results & updates 

 Thank you.